Gilead Sciences Inc. expressed confidence in Yescarta’s overall commercial trajectory despite a slight downturn in sales from the previous quarter during its third quarter earnings call on 24 October. The chimeric antigen receptor T-cell (CAR-T) therapy brought in $118m during the July-through-September period, including $32m in the EU; the overall total was 2% below the second quarter, but up 57% year-over-year.
Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate
The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.
More from Earnings
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.